Nom: Etelcalcetide
Numéro CAS. : 1262780-97-1
Séquence: N-acetyl-D-cysteinyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-alanyl-D-argininamide disulfide with L-cysteine hydrochloride
Formule moléculaire: C38H74ClN21O10S2
Poids moléculaire : 1084.71
Pureté: >98.0%
Source: synthétique
L'ételcalcétide est un récepteur calcimimétique et sensible au calcium. (CaSR) agonist composed of a synthetic peptide comprised of seven D-amino acids that can be used to treat secondary hyperparathyroidism (sHPT) in hemodialysis patients with chronic kidney disease (CKD). Upon intravenous administration, etelcalcetide mimics calcium and allosterically binds to and activates the CaSR expressed by the parathyroid gland. Cela supprime la synthèse et la sécrétion de l'hormone parathyroïdienne (PTH), réduisant ainsi les niveaux de PTH et abaissant les niveaux de calcium et de phosphore sériques. Une PTH élevée est souvent observée chez les patients atteints d'IRC et est associée à une homéostasie dérégulée du phosphate de calcium..
Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland. Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.
Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
